ArticleBMC infectious diseases2026
Ischaemic heart disease is the factor associated with severe COVID-19 in the urban population of Uzbekistan: a single‑center retrospective study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe course of disease development during the coronavirus disease 2019 (COVID-19) pandemic has demonstrated a very wide spectrum, with the most vulnerable group of severe disease comprising > 10% of cases worldwide. Previously, several clinical and laboratory phenotypes have been suggested for the prediction of severe disease courses with different impacts in diverse populations.
methodsUsing a logistic regression model, we performed a study of 227 patients (37% with severe disease), all of whom were ethnically Uzbek, to identify predisease clinical phenotypes associated with disease severity, such as type 2 diabetes (T2D), obesity, hypertension and ischaemic heart disease (IHD), and ascertained the contribution of the angiotensin converting enzyme-encoding gene insertion/deletion (ACE I/D) rs1799752 and the interleukin-28 isoform B (IL28B) gene rs12979860 genetic markers.
resultsWe found that the greatest contribution to the severe disease group from IHD was observed before the start of infection, whereas the contributions of T2D and obesity were only nominally important for the model. Interestingly, the ACE rs1799752 DD genotype together with clinical phenotypes contributed to the discrimination of the severe disease group, but we detected no effect of the IL28B polymorphism. However, without the inclusion of clinical phenotypes in the model, we did not observe a significant ACE polymorphism association with COVID-19 severity (likelihood ratio test p = 0.1). We critically reviewed allelic frequencies for ACE rs1799752 in different populations and studies in an attempt to explain possible discrepancies in previously reported associations in diverse populations.
conclusionsIn a modest group of patients from the Uzbek population, we confirmed the importance of IHD, metabolic disorders and ACE genetics in the development of severe COVID-19 infection in this population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.